Anhui Wanbang Pharmaceutical TechnologyLtd Management
Management criteria checks 2/4
Anhui Wanbang Pharmaceutical TechnologyLtd's CEO is Chunlei Tao, appointed in Aug 2019, has a tenure of 5.42 years. directly owns 39.64% of the company’s shares, worth CN¥1.02B. The average tenure of the management team and the board of directors is 5.4 years and 5.4 years respectively.
Key information
Chunlei Tao
Chief executive officer
CN¥1.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.4yrs |
| CEO ownership | 39.6% |
| Management average tenure | 5.4yrs |
| Board average tenure | 5.4yrs |
Recent management updates
CEO
Chunlei Tao (53 yo)
5.4yrs
Tenure
CN¥1,116,700
Compensation
Ms. Chunlei Tao is General Manager & Chairman of the Board of Anhui Wanbang Pharmaceutical Technology Co., Ltd. since August 22, 2019. She is Co-Owner of Hefei Bairuibang Equity Investment Partnership Ente...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | 5.4yrs | CN¥1.12m | 39.64% CN¥ 1.0b | |
| CFO & Board Secretary | 5.4yrs | CN¥581.50k | no data | |
| Deputy GM & Director | 5.4yrs | CN¥896.00k | no data | |
| Deputy GM & Director | 5.4yrs | CN¥830.50k | no data | |
| Deputy General Manager | no data | CN¥651.50k | no data | |
| Deputy General Manager | no data | CN¥600.70k | no data |
5.4yrs
Average Tenure
41yo
Average Age
Experienced Management: 301520's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | 5.4yrs | CN¥1.12m | 39.64% CN¥ 1.0b | |
| Deputy GM & Director | 5.4yrs | CN¥896.00k | no data | |
| Deputy GM & Director | 5.4yrs | CN¥830.50k | no data | |
| Independent Director | 5.4yrs | CN¥72.00k | no data | |
| Director | 4.4yrs | no data | 2.1% CN¥ 53.8m | |
| Supervisor | 5.4yrs | no data | no data |
5.4yrs
Average Tenure
47.5yo
Average Age
Experienced Board: 301520's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 04:27 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anhui Wanbang Pharmaceutical Technology Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|